Swedish drug developer DexTech's Q4 operating loss widens; reports positive patient outcomes

Dextech Medical AB

31/08/2026 10:59

Overview
Sweden drug developer's fiscal Q4 sales were zero, with operating loss widening yr/yr
Company completed phase I/IIa OsteoDex study in multiple myeloma, meeting primary safety endpoint
DexTech says working capital sufficient to fund operations through end-2028

Outlook
Company says current liquidity is sufficient to finance operations until end of 2028
DexTech to complete clinical study report after all patient follow-up results are available

Result Drivers
CLINICAL STUDY COMPLETION - Co completed phase I/IIa OsteoDex study in multiple myeloma, meeting primary safety endpoint and reporting no significant ODX-related adverse events
POSITIVE PATIENT OUTCOMES - All treated patients transitioned from progressive to stable disease during ODX treatment; more than 70% retained stable disease after treatment

Company press release: ID:nWkr409j5Z

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
 
SEK 0
 
Q4 Loss Per Share
 
SEK 0.10
 
Q4 Operating Profit
 
-SEK 1.9 mln
 

Reuters Recommended Reads
Aug 28 - Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)